The 5 most-read breast cancer articles on AJMC.com this year included FDA approvals, emerging therapies for metastatic breast ...
The U.S. Food and Drug Administration (FDA) has approved Enhertu (fam-trastuzumab deruxtecan-nxki) in combination with ...
The FDA approved niraparib and abiraterone acetate (Akeega) in combination with prednisone for treating BRCA2 -mutated ...
All eyes are on what could be a precedent-setting case at the Council for Medical Schemes as a former champion athlete takes ...
An incredible Christmas lights display run by a cancer survivor and her engineer husband has helped raise £5,000 for Rosemere ...
Khaleej Times on MSN
US FDA approves AstraZeneca, Daiichi's breast cancer drug as first-line treatment
The US Food and Drug Administration has approved Daiichi Sankyo's therapy in combination with Roche's drug for the first-line ...
Dec 15 (Reuters) - The U.S. Food and Drug Administration has approved Daiichi Sankyo's therapy in combination with Roche's ...
In this video, Erica L. Mayer, MD, MPH, discusses data from the phase 3 lidERA trial demonstrating that giredestrant improved disease-free survival in early-stage, hormone receptor-positive, ...
Akeega combines niraparib, a PARP inhibitor, and abiraterone acetate, a CYP17 inhibitor, into a single tablet for BRCA2-mutated mCSPC.
Stage 4 metastatic breast cancer presents significant emotional and psychological challenges, requiring patients to adapt ...
Opinion
A trans woman's cancer symptoms were almost missed — until gender affirming care saved her life
But when Trefzger went under the knife for facial feminization surgery, she had a stroke that caused blindness in her left eye. This was a tragic outcome, but the scans done in the wake of her stroke ...
This study came out of a multi-institutional collaboration called the BRCA BCY group, which is an international group of ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback